Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub 2011 Sep 24.
Retèl V.P., Joore M.A., van Harten W.H.
The 21-gene has the highest probability of being cost-effective when focusing on cost/LY, while focusing on cost/QALY, the 70-gene signature was most cost-effective.
Read more: Breast Cancer Res Treat_Retel et al_The 21-gene has the highest probability of being cost-effective… 2012